Kodiak Sciences is a clinical stage company developing innovative therapeutics to treat high prevalence ophthalmic diseases. We aspire to global leadership in ophthalmology through internal focus and by aggregating top talent, technologies, discoveries and ideas. Our Antibody Biopolymer Conjugate Platform merges the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak’s discovery engine. In addition to its lead product candidate, KSI-301, a potential best in class molecule for age-related macular degeneration and diabetic retinopathy, Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases such as wet AMD and diabetic retinopathy. Kodiak is based in Palo Alto, CA.